1CG Stock Overview

A gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. More details

1CG fundamental analysis
Snowflake Score
Valuation	4/6
Future Growth	2/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Trading at 75.5% below our estimate of its fair value

Revenue is forecast to grow 57.06% per year

Risk Analysis

Shares are highly illiquid

Currently unprofitable and not forecast to become profitable over the next 3 years

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

CRISPR Therapeutics AG Competitors

Biotest

XTRA:BIO3

€1.4b

Heidelberg Pharma

XTRA:HPHA

€150.5m

Formycon

XTRA:FYB

€404.3m

SCHOTT Pharma KGaA

XTRA:1SXP

€3.9b

Price History & Performance

Summary of share price highs, lows and changes for CRISPR Therapeutics
Historical stock prices
Current Share Price	US$32.40
52 Week High	US$34.20
52 Week Low	US$29.20
Beta	1.87
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	111.07%

Recent News & Updates

No updates

Recent updates

No updates

Shareholder Returns

	1CG	DE Biotechs	DE Market
7D	0%	-0.3%	0.8%
1Y	n/a	-12.7%	14.6%

Return vs Industry: Insufficient data to determine how 1CG performed against the German Biotechs industry.

Return vs Market: Insufficient data to determine how 1CG performed against the German Market.

Price Volatility

Is 1CG's price volatile compared to industry and market?
1CG volatility
1CG Average Weekly Movement	n/a
Biotechs Industry Average Movement	5.7%
Market Average Movement	6.6%
10% most volatile stocks in DE Market	12.7%
10% least volatile stocks in DE Market	3.1%

Stable Share Price: 1CG's share price has been volatile over the past 3 months compared to the German market.

Volatility Over Time: Insufficient data to determine 1CG's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2013	393	Sam Kulkarni	www.crisprtx.com

CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company’s CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.

CRISPR Therapeutics AG Fundamentals Summary

How do CRISPR Therapeutics's earnings and revenue compare to its market cap?
1CG fundamental statistics
Market cap	€3.00b
Earnings (TTM)	-€345.90m
Revenue (TTM)	€33.79m

88.9x

P/S Ratio

-8.7x

P/E Ratio

Is 1CG overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
1CG income statement (TTM)
Revenue	US$37.68m
Cost of Revenue	US$437.76m
Gross Profit	-US$400.08m
Other Expenses	-US$14.43m
Earnings	-US$385.66m

Last Reported Earnings

Mar 31, 2025

Next Earnings Date

n/a

Earnings per share (EPS)	-4.47
Gross Margin	-1,061.93%
Net Profit Margin	-1,023.64%
Debt/Equity Ratio	0%

How did 1CG perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2025/05/18 06:52
End of Day Share Price	2025/05/16 00:00
Earnings	2025/03/31
Annual Earnings	2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

CRISPR Therapeutics AG is covered by 44 analysts. 24 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Analyst	Institution
Jack Allen	Baird
Huidong Wang	Barclays
Konstantinos Biliouris	BMO Capital Markets Equity Research